| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6182888 | Gynecologic Oncology | 2012 | 6 Pages |
Abstract
⺠Gemcitabine and tanespimycin combination therapy was well tolerated but had limited clinical activity. ⺠Modest downregulation of Chk-1 was observed in clinical samples, but reliable downregulation of HSP90 or client proteins was not observed. ⺠Based on clinical response and correlative studies, limited response is likely due to inadequate downregulation of HSP90 client proteins at therapeutically achievable concentrations.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Andrea E. Wahner Hendrickson, Ann L. Oberg, Gretchen Glaser, John K. Camoriano, Prema P. Peethambaram, Gerardo Colon-Otero, Charles Erlichman, S. Percy Ivy, Scott H. Kaufmann, Larry M. Karnitz, Paul Haluska,